Catalog No.: PC-45870Not For Human Use, Lab Use Only.
CX-4945 (Silmitasertib, CX4945) is a potent, selective, orally bioavailable, ATP-competitive inhibitor of protein kinase Casein Kinase 2 (CK2) with Ki of 0.38 nM, CK2α IC50 of 1 nM.
CX4945 (Silmitasertib, CX-4945) is a potent, selective, orally bioavailable, ATP-competitive inhibitor of protein kinase Casein Kinase 2 (CK2) with Ki of 0.38 nM, CK2α IC50 of 1 nM.
CX4945 (Silmitasertib) displays good selectivity profile against a panel of 238 kinases.
CX4945 (Silmitasertib) attenuates PI3K/Akt signaling, blocks CK2-dependent HIF-1α transcription, caused cell cycle arrest and selectively induces apoptosis in cancer cells relative to normal cells.
CX4945 (Silmitasertib) exhibits antitumor efficacy in murine xenograft models.
